Sofinnova Partners

Congratulations to Sitryx, a Sofinnova Partners portfolio company, on the Phase I initiation of its potential atopic dermatitis (SYX-5219) treatment. This is the second program from the Sitryx portfolio to enter clinical development and offers first-in-class potential as an oral, disease-modifying anti-inflammatory therapy targeting pyruvate kinase M2 (PKM2), a critical enzyme that regulates cell metabolism.   Learn more in the link below and in the comments. Maina Bhaman, Anta Gkelou, Zhizhong Joel Y..

As #BioEuropeSpring 2025 wraps up, we’re sharing key insights from panels moderated by Sofinnova Partners’ Paola Pozzi and Maria Gabriella Camboni.   - Paola Pozzi moderated a deep dive into the future of cell and gene therapy with industry experts Karen AIACH PIGNET, Natalia Misciattelli Mocenigo Soranzo, and Francesca Pasinelli. The panel explored recent advancements, current gaps, and what’s needed to unlock the full potential of this field. - Maria Gabriella Camboni led a session on turning concepts into companies, featuring insights from Daniela Bellomo, Celine Bouquet, and Robin Carr. Key takeaways for success? Strong science, ironclad evidence, and a unique solution to a real problem.   Our team had a great time connecting with new and old industry friends. Thank you, Michelle Cheesbrough and Avisha Amalean, for another great edition!

Congratulations to Moon Surgical, a Sofinnova Partners MDStart portfolio company, on its FDA clearance for ScoPilot™, the first AI application to run intraoperatively on a commercially available robotic platform equipped with NVIDIA Holoscan. This is Moon's third FDA approval within the last three years. This milestone underscores Moon Surgical’s ability to drive AI-powered advancements in and around the operating theatre.   Link to full announcement below and in the comments. Anne Osdoit, Antoine Papiernik, Jeffery Alvarez

Il Sole 24 Ore’s Francesca Cerati spoke with Graziano Seghezzi about Sofinnova Biovelocita’s II €165M capital dedicated for European biotech acceleration. “In 2015, we created Italy’s first accelerator dedicated to biotechnology, called Biovelocita, as a sort of prototype to understand whether and how all the acceleration activities within our platform could also be applied to biotechnology," recalls Graziano Seghezzi of Sofinnova Partners. "We chose to start in Italy because we wanted to bring together the three fundamental ingredients for acceleration: top-tier science, an experienced and capable management team—like Silvano Spinelli and Maria Gabriella Camboni—and dedicated life sciences capital, all within the same 'house' to accelerate these projects."

📰 Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership. SIGNADORI BIO, a novel cell therapy platform, emerges from collaboration with scientific founders Dr. Jean-Luc PERFETTINI and Professor Nathalie CHAPUT. Read press release ⤵ https://lnkd.in/ejvc6UA6

#Newsroom   Sofinnova Partners, una delle principali società di #𝘃𝗲𝗻𝘁𝘂𝗿𝗲𝗰𝗮𝗽𝗶𝘁𝗮𝗹 europee nel settore delle 𝘀𝗰𝗶𝗲𝗻𝘇𝗲 𝗱𝗲𝗹𝗹𝗮 𝘃𝗶𝘁𝗮 con sedi a Parigi, Londra e Milano, ha annunciato oggi il final closing di 𝗦𝗼𝗳𝗶𝗻𝗻𝗼𝘃𝗮 𝗕𝗶𝗼𝘃𝗲𝗹𝗼𝗰𝗶𝘁𝗮 𝗜𝗜. Il fondo ha superato il proprio target, raccogliendo con successo 165 milioni di euro, con un determinante sostegno delle principali aziende farmaceutiche globali, tra cui Amgen, Bristol Myers Squibb e Pfizer Ventures. Questo traguardo segna una significativa espansione della 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗮 𝗱𝗶 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘇𝗶𝗼𝗻𝗲 #𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗱𝗶 𝗦𝗼𝗳𝗶𝗻𝗻𝗼𝘃𝗮, che oltrepassa i confini dell’Italia per includere anche Francia, Regno Unito e Danimarca, con l’ambizione di raggiungere ulteriori paesi europei in futuro.   “La nostra sottoscrizione nel Fondo Biovelocita nasce dal comune obiettivo di mettere a sistema competenze tecniche e finanziarie con la piattaforma di trasferimento tecnologico che abbiamo realizzato come CDP Venture Capital in Italia, e co-disegnare un modello di investimento internazionale, che possa sostenere questo percorso anche in altri Paesi europei”, commenta Claudia Pingue, 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗮𝗯𝗶𝗹𝗲 𝗙𝗼𝗻𝗱𝗼 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗧𝗿𝗮𝗻𝘀𝗳𝗲𝗿 𝗱𝗶 𝗖𝗗𝗣 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹. ➡️ Scopri di più, leggi il comunicato stampa: https://lnkd.in/d-zhC5Hn

As a Partner in Sofinnova Biovelocita II, Zhizhong "Joel" Y. is helping redefine biotech investment. With a background in chemistry and systems biology, Zhizhong takes a hands-on approach to funding and building early-stage biotech companies. Through the Biovelocita strategy, he helps transform ideas into investable companies – providing financing at the earliest stages as they develop into scientific projects, even before a company is formed, while ensuring dedicated capital along the way. Learn more about Zhizhong in the link in comments.

Forth Therapeutics emerges from stealth! Led by Alex Leech, serial entrepreneur and a Partner at Sofinnova Partners, Forth Tx is pushing the boundaries of next-generation precision therapeutics for fibrosis. With headquarters in Edinburgh and Cambridge, the company is built on pioneering research from Neil Henderson, MD PhD FMedSci, a world-renowned expert in fibrosis and tissue regeneration at the The University of Edinburgh. Excited to see Forth Tx drive innovation in this critical space! Learn more about both Alex Leech and Forth Therapeutics in the links in the comments. 

Introducing SIGNADORI BIO, the first company born from Sofinnova Partners’ collaboration with Gustave Roussy, Europe’s #1 cancer research center. Matthieu Coutet is leading the charge—an entrepreneur first and VC Partner, with two decades of experience building startups. His hands-on company-building expertise makes him the perfect fit to drive Signadori forward. This milestone is a testament to our strategic partnership and shared mission:, accelerating biotech innovation by transforming scientific research into ground breaking therapies. Learn more about Matthieu Coutet and SIGNADORI BIO in the links in the comments. 

BioClec—launches with Maria Gabriella Camboni at the helm. A serial entrepreneur, clinical pharmacologist, and Partner at Sofinnova Partners, Gabriella has played a key role in shaping Italy’s biotech ecosystem – from co-founding the country’s first biotech accelerator, to now creating BioClec, one of three companies launching today under Biovelocita II, Sofinnova’s €165M biotech acceleration fund. Still in its discovery phase, BioClec is pioneering disease-modifying interventions targeting a novel microglial pathway in Alzheimer’s. Based in Italy, this launch strengthens Sofinnova’s commitment to neuroscience and biotech innovation in the region. Learn more about Gabriella and BioClec in the links in the comments.